Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

NCT02676349 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Carcinoma

Interventions

DRUG: mFolfirinox
RADIATION: Chemoradiotherapy
PROCEDURE: surgery
DRUG: Adjuvant chemotherapy

Sponsor

Institut de Cancérologie de Lorraine